Refine by
Laboratory Data Articles & Analysis
36 news found
Following the generation of successful results with the University of Michigan through the ACE program, Predictive Oncology is now actively calling for submissions for a new cohort of compounds to be tested in Q4 2025. ACE program participation is offered exclusively to academic institutions and provides access to the POAI proprietary active ML/AI and biobank of primary patient ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an update from the Company’s work with biopharma company Boundless Bio. ...
We’ll design the most appropriate technology combination according to your project and help researchers obtain higher-quality scientific research data,” he further added. About Creative Proteomics Creative Proteomics is an innovative contract research organization that focuses on using advanced equipment platforms and optimized detection technologies to help ...
We will choose the right technology combination according to your project and help researchers obtain higher-quality scientific research data,” he further added. About Creative Proteomics Creative Proteomics is an innovative contract research organization that focuses on using advanced equipment platforms and optimized detection technology to help researchers around the ...
The company has a proprietary laboratory information management system to strengthen laboratory quality monitoring and quality management and ensure the efficiency and security of customer data. ...
We will choose the most proper technology combination according to your project, meet your various needs, and help researchers obtain higher-quality scientific research data,” stated Creative Proteomics’s senior scientist. “To identify specific cytokines involved in any inflammatory or immune response, we often need to screen for cytokines, which requires ...
V-Wave Ltd, manufacturer of the V-Wave Ventura investigational interatrial shunt device to help patients with advanced heart failure (HF), announced 12-month echocardiographic results from the open label Roll-in arm of the RELIEVE-HF pivotal clinical trial, comprising 97 NYHA Class III or ambulatory Class IV HF patients who were already on maximally tolerated guideline directed medical therapy. ...
We will choose the right technology combination according to your project, meet your various needs, and help researchers obtain higher-quality scientific research data,” stated Creative Proteomics’s senior scientist. Creative Proteomics can provide a tumor necrosis factor detection platform for scientific research. ...
The Bioinformatics-analysis division is a new division of CD Genomics that provides reliable next-generation and third-generation high-throughput sequencing data analysis, comprehensive technology services, database construction, and other related data analysis services. CD Genomics recently launched various types of genotyping analysis services, including ...
Recently, CD Genomics announced the launch of the Microarray Data Analysis service to help scientists discover the biological significance of microarray data and, at the same time, help reduce the time and cost of wet laboratory experiments and data generation. ...
Creative Proteomics Cytokine recently announced Disease Cytokine Assays to help researchers obtain higher quality scientific research data. Cytokines, including interleukins, interferons, tumor necrosis factors, and chemokines, can play key pro- and anti-inflammatory roles in vivo through a variety of biochemical pathways and interactions. ...
This partnership will also add a new state-of-the-art dedicated laboratory to accelerate the advancement of Amgen’s R&D projects. ...
ByBiocon
Hyperfine, Inc. (Nasdaq: HYPR) (“Hyperfine”), creator of the first U.S. Food and Drug Administration (“FDA”) cleared portable magnetic resonance imaging (“MRI”)TM device, Swoop®, is proud to announce that M Health Fairview is deploying a Swoop system in the emergency room (ER), intensive care unit (ICU) and post anesthesia environments at M Health Fairview ...
“Clinical research has been a number one priority for our practice since our doors opened almost 40 years ago. We’ve worked hard to build and expand our clinical trial program so that all of our patients have every possible option to receive access to the newest therapies in development,” said Steven Duffy, MD at HOA CNY. “We’re delighted to partner with Deep Lens ...
The company has a proprietary laboratory information management system to strengthen laboratory quality monitoring and quality management to ensure the efficiency and security of customer data. ...
Deep Lens and Ventura County Hematology Oncology Specialists today announced that they have entered into a strategic agreement that will expand clinical trial opportunities for patients in the Ventura county area. As part of this collaboration, Ventura County Hematology Oncology Specialists will integrate Deep Lens’ artificial intelligence (AI) based clinical trial matching solution and ...
Through Deep Lens’ proprietary AI-based trial matching solution, VIPER, new patient data is being ingested and updated on a continuous basis from its robust Unity Network of community-based oncology practices. Instead of relying on historical data, Real Time Feasibility surfaces the patients that are eligible for trials now, and more importantly, those who ...
ILEX Medical is a leading company in the medical diagnostics field and specializes in marketing as well as selling and maintaining equipment, disposables and reagents to laboratories and healthcare establishments in Israel. The ILEX Group is closely affiliated with leading multinational medical conglomerates, like Abbott, Hologic, Grifols, BioMerieux, IL Sebia, and Fertilitech, ...
” Deep Lens’ VIPER will pre-screen all patients from Southern Oncology Specialists’ EMR (OncoEMR) and integrate molecular data feeds from Caris Life Sciences, Guardant Health, Foundation Medicine and Tempus as well as all pathology feeds to automatically identify qualified patients for clinical trials. ...
Ocala Oncology/Florida Cancer Affiliates and Deep Lens today announced that they have entered into a strategic agreement to expand the well-established clinical research program and offering to patients at the Ocala-based practice. The collaboration will leverage Deep Lens’ artificial intelligence-based clinical trial matching solution, VIPERTM, and other support services to identify the ...